Evidence map›Paper›PMID 36012541›Full record

ArticleInternational journal of molecular sciences2022

Unveiling the Ability of Witch Hazel (

Stefano Piazza, Giulia Martinelli, Andrea Magnavacca, Marco Fumagalli, Carola Pozzoli, Massimo Terno, Luisa Canilli, Marco Angarano, Nicole Maranta, Mario Dell'Agli and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Comparative Analysis of Polyphenol-Rich Extracts fromMolecules (Basel, Switzerland) · 2025
    Article
  7. Molecules (Basel, Switzerland) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Stefano PiazzaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-2470-6038
Giulia MartinelliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-0742-0521
Andrea MagnavaccaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-3361-0185
Marco FumagalliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Carola PozzoliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Massimo TernoGanassini Institute S.p.A. (Istituto Ganassini), 20139 Milan, Italy.
Luisa CanilliGanassini Institute S.p.A. (Istituto Ganassini), 20139 Milan, Italy.
Marco AngaranoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0001-8632-4660
Nicole MarantaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Mario Dell'AgliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0001-5378-402X
Enrico SangiovanniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0003-2811-8628
University of Milan · IT

Funding

Istituto Ganassini Spa di Ricerche Biochimiche InflamaskinMinistry of Education, Universities and Research Progetto Eccellenza
6 · The paper itself

Abstract

Hamamelis virginiana L. bark extract is a traditional remedy for skin affections, including atopic dermatitis/eczema (AD). Hamamelis preparations contain tannins, including hamamelitannin (HT), although their pharmacological role in AD is still unknown. This study aimed to study the rational for its topical use by considering the impact of crucial biomarkers on AD pathogenesis. A standardized extract (HVE) (0.5−125 μg/mL) was compared to hamamelitannin (HT), its main compound (0.5−5 μg/mL), in a model of human keratinocytes (HaCaTs), challenged with an AD-like cytokine milieu (TNF-α, IFN-γ, and IL-4). HVE inhibited the release of mediators involved in skin autoimmunity (IL-6 and IL-17C) and allergy (TSLP, IL-6, CCL26, and MMP-9) with a concentration-dependent fashion (IC50s < 25 μg/mL). The biological mechanism was ascribed, at least in part, to the impairment of the NF-κB-driven transcription. Moreover, HVE counteracted the proliferative effects of IL-4 and recovered K10, a marker of skin differentiation. Notably, HT showed activity on well-known targets of IL-4 pathway (CCL26, K10, cell proliferation). To the best of our knowledge, this work represents the first demonstration of the potential role of Hamamelis virginiana in the control of AD symptoms, such as itch and skin barrier impairment, supporting the relevance of the whole phytocomplex.

Indexed as

Dermatitis, AtopicHamamelisCytokinesHumansInterleukin-4Interleukin-6KeratinocytesPlant BarkPlant ExtractsSkinCytokinesInterleukin-4Interleukin-6Plant Extractsallergyatopic dermatitiseczemaHamamelis virginianaphytotherapywitch hazel

Identifiers

PMID36012541
PMCPMC9408886
OpenAlexW4292163691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.